Cargando…
Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil
BACKGROUND: To evaluate the determinants of intensive insulin regimens (ITs) in patients with type 1 diabetes (T1D). METHODS: This multicenter study was conducted between December 2008 and December 2010 in 28 public clinics in 20 Brazilian cities. Data were obtained from 3,591 patients (56.0% female...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052842/ https://www.ncbi.nlm.nih.gov/pubmed/24920963 http://dx.doi.org/10.1186/1758-5996-6-67 |
_version_ | 1782320298389929984 |
---|---|
author | Gomes, Marilia Brito Negrato, Carlos Antonio Cobas, Roberta Tannus, Lucianne Righeti Monteiro Gonçalves, Paolla Ribeiro da Silva, Pedro Carlos Barreto Carneiro, João Regis Ivar Matheus, Alessandra Saldanha Mattos Dib, Sergio Atala Azevedo, Mirela Jobim Nery, Márcia Rodacki, Melanie Zajdenverg, Lenita Montenegro Junior, Renan Magalhães Sepulveda, Janice Calliari, Luis Eduardo Jezini, Deborah Braga, Neuza Luescher, Jorge L Berardo, Renata S Arruda-Marques, Maria Carmo Noronha, Renata M Manna, Thais D Salvodelli, Roberta Penha, Fernanda G Foss, Milton C Foss-Freitas, Maria C Pires, Antonio C Robles, Fernando C Guedes, Maria de Fátima S Dualib, Patricia Silva, Saulo C Sampaio, Emerson Rea, Rosangela Faria, Ana Cristina R Tschiedel, Balduino Lavigne, Suzana Canani, Luis Henrique Zucatti, Alessandra T Coral, Marisa Helena C Pereira, Daniela Aline Araujo, Luiz Antonio Tolentino, Monica Pedrosa, Hermelinda C Prado, Flaviane A Rassi, Nelson Araujo, Leticia B Fonseca, Reine Marie C Guedes, Alexis D Matos, Odelissa S Palma, Catia C Azulay, Rossana Forti, Adriana C Façanha, Cristina Montenegro, Ana Paula Melo, Naira H Rezende, Karla F Ramos, Alberto Felicio, João Soares Santos, Flavia M |
author_facet | Gomes, Marilia Brito Negrato, Carlos Antonio Cobas, Roberta Tannus, Lucianne Righeti Monteiro Gonçalves, Paolla Ribeiro da Silva, Pedro Carlos Barreto Carneiro, João Regis Ivar Matheus, Alessandra Saldanha Mattos Dib, Sergio Atala Azevedo, Mirela Jobim Nery, Márcia Rodacki, Melanie Zajdenverg, Lenita Montenegro Junior, Renan Magalhães Sepulveda, Janice Calliari, Luis Eduardo Jezini, Deborah Braga, Neuza Luescher, Jorge L Berardo, Renata S Arruda-Marques, Maria Carmo Noronha, Renata M Manna, Thais D Salvodelli, Roberta Penha, Fernanda G Foss, Milton C Foss-Freitas, Maria C Pires, Antonio C Robles, Fernando C Guedes, Maria de Fátima S Dualib, Patricia Silva, Saulo C Sampaio, Emerson Rea, Rosangela Faria, Ana Cristina R Tschiedel, Balduino Lavigne, Suzana Canani, Luis Henrique Zucatti, Alessandra T Coral, Marisa Helena C Pereira, Daniela Aline Araujo, Luiz Antonio Tolentino, Monica Pedrosa, Hermelinda C Prado, Flaviane A Rassi, Nelson Araujo, Leticia B Fonseca, Reine Marie C Guedes, Alexis D Matos, Odelissa S Palma, Catia C Azulay, Rossana Forti, Adriana C Façanha, Cristina Montenegro, Ana Paula Melo, Naira H Rezende, Karla F Ramos, Alberto Felicio, João Soares Santos, Flavia M |
author_sort | Gomes, Marilia Brito |
collection | PubMed |
description | BACKGROUND: To evaluate the determinants of intensive insulin regimens (ITs) in patients with type 1 diabetes (T1D). METHODS: This multicenter study was conducted between December 2008 and December 2010 in 28 public clinics in 20 Brazilian cities. Data were obtained from 3,591 patients (56.0% female, 57.1% Caucasian). Insulin regimens were classified as follows: group 1, conventional therapy (CT) (intermediate human insulin, one to two injections daily); group 2 (three or more insulin injections of intermediate plus regular human insulin); group 3 (three or more insulin injections of intermediate human insulin plus short-acting insulin analogues); group 4, basal-bolus (one or two insulin injections of long-acting plus short-acting insulin analogues or regular insulin); and group 5, basal-bolus with continuous subcutaneous insulin infusion (CSII). Groups 2 to 5 were considered IT groups. RESULTS: We obtained complete data from 2,961 patients. Combined intermediate plus regular human insulin was the most used therapeutic regimen. CSII was used by 37 (1.2%) patients and IT by 2,669 (90.2%) patients. More patients on IT performed self-monitoring of blood glucose and were treated at the tertiary care level compared to CT patients (p < 0.001). The majority of patients from all groups had HbA1c levels above the target. Overweight or obesity was not associated with insulin regimen. Logistic regression analysis showed that economic status, age, ethnicity, and level of care were associated with IT (p < 0.001). CONCLUSIONS: Given the prevalence of intensive treatment for T1D in Brazil, more effective therapeutic strategies are needed for long term-health benefits. |
format | Online Article Text |
id | pubmed-4052842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-40528422014-06-12 Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil Gomes, Marilia Brito Negrato, Carlos Antonio Cobas, Roberta Tannus, Lucianne Righeti Monteiro Gonçalves, Paolla Ribeiro da Silva, Pedro Carlos Barreto Carneiro, João Regis Ivar Matheus, Alessandra Saldanha Mattos Dib, Sergio Atala Azevedo, Mirela Jobim Nery, Márcia Rodacki, Melanie Zajdenverg, Lenita Montenegro Junior, Renan Magalhães Sepulveda, Janice Calliari, Luis Eduardo Jezini, Deborah Braga, Neuza Luescher, Jorge L Berardo, Renata S Arruda-Marques, Maria Carmo Noronha, Renata M Manna, Thais D Salvodelli, Roberta Penha, Fernanda G Foss, Milton C Foss-Freitas, Maria C Pires, Antonio C Robles, Fernando C Guedes, Maria de Fátima S Dualib, Patricia Silva, Saulo C Sampaio, Emerson Rea, Rosangela Faria, Ana Cristina R Tschiedel, Balduino Lavigne, Suzana Canani, Luis Henrique Zucatti, Alessandra T Coral, Marisa Helena C Pereira, Daniela Aline Araujo, Luiz Antonio Tolentino, Monica Pedrosa, Hermelinda C Prado, Flaviane A Rassi, Nelson Araujo, Leticia B Fonseca, Reine Marie C Guedes, Alexis D Matos, Odelissa S Palma, Catia C Azulay, Rossana Forti, Adriana C Façanha, Cristina Montenegro, Ana Paula Melo, Naira H Rezende, Karla F Ramos, Alberto Felicio, João Soares Santos, Flavia M Diabetol Metab Syndr Research BACKGROUND: To evaluate the determinants of intensive insulin regimens (ITs) in patients with type 1 diabetes (T1D). METHODS: This multicenter study was conducted between December 2008 and December 2010 in 28 public clinics in 20 Brazilian cities. Data were obtained from 3,591 patients (56.0% female, 57.1% Caucasian). Insulin regimens were classified as follows: group 1, conventional therapy (CT) (intermediate human insulin, one to two injections daily); group 2 (three or more insulin injections of intermediate plus regular human insulin); group 3 (three or more insulin injections of intermediate human insulin plus short-acting insulin analogues); group 4, basal-bolus (one or two insulin injections of long-acting plus short-acting insulin analogues or regular insulin); and group 5, basal-bolus with continuous subcutaneous insulin infusion (CSII). Groups 2 to 5 were considered IT groups. RESULTS: We obtained complete data from 2,961 patients. Combined intermediate plus regular human insulin was the most used therapeutic regimen. CSII was used by 37 (1.2%) patients and IT by 2,669 (90.2%) patients. More patients on IT performed self-monitoring of blood glucose and were treated at the tertiary care level compared to CT patients (p < 0.001). The majority of patients from all groups had HbA1c levels above the target. Overweight or obesity was not associated with insulin regimen. Logistic regression analysis showed that economic status, age, ethnicity, and level of care were associated with IT (p < 0.001). CONCLUSIONS: Given the prevalence of intensive treatment for T1D in Brazil, more effective therapeutic strategies are needed for long term-health benefits. BioMed Central 2014-05-31 /pmc/articles/PMC4052842/ /pubmed/24920963 http://dx.doi.org/10.1186/1758-5996-6-67 Text en Copyright © 2014 Gomes et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Gomes, Marilia Brito Negrato, Carlos Antonio Cobas, Roberta Tannus, Lucianne Righeti Monteiro Gonçalves, Paolla Ribeiro da Silva, Pedro Carlos Barreto Carneiro, João Regis Ivar Matheus, Alessandra Saldanha Mattos Dib, Sergio Atala Azevedo, Mirela Jobim Nery, Márcia Rodacki, Melanie Zajdenverg, Lenita Montenegro Junior, Renan Magalhães Sepulveda, Janice Calliari, Luis Eduardo Jezini, Deborah Braga, Neuza Luescher, Jorge L Berardo, Renata S Arruda-Marques, Maria Carmo Noronha, Renata M Manna, Thais D Salvodelli, Roberta Penha, Fernanda G Foss, Milton C Foss-Freitas, Maria C Pires, Antonio C Robles, Fernando C Guedes, Maria de Fátima S Dualib, Patricia Silva, Saulo C Sampaio, Emerson Rea, Rosangela Faria, Ana Cristina R Tschiedel, Balduino Lavigne, Suzana Canani, Luis Henrique Zucatti, Alessandra T Coral, Marisa Helena C Pereira, Daniela Aline Araujo, Luiz Antonio Tolentino, Monica Pedrosa, Hermelinda C Prado, Flaviane A Rassi, Nelson Araujo, Leticia B Fonseca, Reine Marie C Guedes, Alexis D Matos, Odelissa S Palma, Catia C Azulay, Rossana Forti, Adriana C Façanha, Cristina Montenegro, Ana Paula Melo, Naira H Rezende, Karla F Ramos, Alberto Felicio, João Soares Santos, Flavia M Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title | Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title_full | Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title_fullStr | Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title_full_unstemmed | Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title_short | Determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in Brazil |
title_sort | determinants of intensive insulin therapeutic regimens in patients with type 1 diabetes: data from a nationwide multicenter survey in brazil |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052842/ https://www.ncbi.nlm.nih.gov/pubmed/24920963 http://dx.doi.org/10.1186/1758-5996-6-67 |
work_keys_str_mv | AT gomesmariliabrito determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT negratocarlosantonio determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT cobasroberta determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT tannusluciannerighetimonteiro determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT goncalvespaollaribeiro determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT dasilvapedrocarlosbarreto determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT carneirojoaoregisivar determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT matheusalessandrasaldanhamattos determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT dibsergioatala determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT azevedomirelajobim determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT nerymarcia determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT rodackimelanie determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT zajdenverglenita determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT montenegrojuniorrenanmagalhaes determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT sepulvedajanice determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT calliariluiseduardo determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT jezinideborah determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT braganeuza determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT luescherjorgel determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT berardorenatas determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT arrudamarquesmariacarmo determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT noronharenatam determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT mannathaisd determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT salvodelliroberta determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT penhafernandag determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT fossmiltonc determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT fossfreitasmariac determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT piresantonioc determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT roblesfernandoc determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT guedesmariadefatimas determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT dualibpatricia determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT silvasauloc determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT sampaioemerson determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT rearosangela determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT fariaanacristinar determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT tschiedelbalduino determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT lavignesuzana determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT cananiluishenrique determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT zucattialessandrat determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT coralmarisahelenac determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT pereiradanielaaline determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT araujoluizantonio determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT tolentinomonica determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT pedrosahermelindac determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT pradoflavianea determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT rassinelson determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT araujoleticiab determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT fonsecareinemariec determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT guedesalexisd determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT matosodelissas determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT palmacatiac determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT azulayrossana determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT fortiadrianac determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT facanhacristina determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT montenegroanapaula determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT melonairah determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT rezendekarlaf determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT ramosalberto determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT feliciojoaosoares determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil AT santosflaviam determinantsofintensiveinsulintherapeuticregimensinpatientswithtype1diabetesdatafromanationwidemulticentersurveyinbrazil |